<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643979</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-2139</org_study_id>
    <nct_id>NCT02643979</nct_id>
  </id_info>
  <brief_title>Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy</brief_title>
  <official_title>Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol is one of the most popular anesthetic drugs used for sedation during upper
      gastrointestinal endoscopies due to its quick onset and quick resolution of symptoms allowing
      patients to leave the hospital sooner. However, when administered it can also slow the
      breathing of patients and cause others to have upper airway obstruction (such as snoring)
      which can impede proper spontaneous breathing. Ketamine is an agent that is capable of
      providing both pain control and sedation while having either minimal effect on breathing or
      promoting spontaneous breathing. Combining Ketamine with Propofol has the potential to reduce
      the total amount of Propofol used resulting in a procedure being performed under the same
      level of sedation but without the downside of reduced spontaneous breathing. Patients who are
      obese (defined as body mass index greater than 35) tend to be even more susceptible to this
      effect of Propofol. The researchers are investigating whether the addition of Ketamine will
      indeed allow for this continued comfortable level of sedation while promoting continued
      spontaneous breathing in obese patients undergoing upper gastrointestinal endoscopies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon patient arrival to endoscopy suite heart rate (HR), pre-procedure baseline blood
      pressure (BP), and pre-procedure oxygen saturation (SPO2) via pulse oximeter are recorded in
      endoscopy holding area, patient alertness and orientation assessed (respond to name, know the
      state, know the hospital, know the year, know the season).

      Once the subject enters the endoscopy suite monitors are placed to record starting BP, HR,
      SPO2 recorded, nasal cannula with end tidal carbon dioxide (CO2) monitor attached, and 5-lead
      ECG.

      Following time out patient given 100mg Lidocaine IV bolus, 1-minute delay, then
      study-provided syringe administered. Once patient assessed to produce an RSS score &gt;5 (Asleep
      with sluggish response to glabellar tap or NO response) endoscopy proceeds.

      Recorder (blinded) notes if initially provided syringe alone was enough to produce an RSS &gt;5,
      notes subject's response to endoscopy insertion (presence or absence of gagging), notes
      amount of additional propofol required to maintain adequate conditions to continue endoscopy,
      records non-invasive blood pressure (NIBP) at 3-minute intervals, notes for level of airway
      obstruction (obstruction with continued air movement, obstruction requiring chin lift or jaw
      thrust for relief, obstruction requiring progression to assisted ventilation or intubation),
      notes for desaturation events (SPO2 &lt;90% with a coherent waveform).

      At the end of the procedure the total anesthesia time is recorded, total procedure
      start-to-finish time recorded, total dose of propofol recorded, and any incidence of patient
      agitation noted.

      Once in recovery the recovery room admission HR, SPO2, NIBP recorded followed by admission
      +15 minutes HR, SPO2, and NIBP, any incidence of desaturation (&lt;90% SPO2 with waveform)
      recorded, incidence of airway obstruction (with air movement, requiring airway maneuver,
      requiring intervention) recorded, time until patient is alert and oriented recorded (response
      to name, able to state what state they are in, able to state what hospital they are in, able
      to state the year, able to state the season), time-until-recovered recorded (Modified Aldrete
      Score &gt; 9), incidence of nausea prior to recovery recorded, incidence of vomiting prior to
      recovery recorded, incidence of agitation or delirium prior to recovery recorded.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Enrollment
  </why_stopped>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">January 5, 2019</completion_date>
  <primary_completion_date type="Actual">January 5, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gagging Reaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with gagging or &quot;vomit-like&quot; reaction on endoscopic insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Type of Airway Obstruction</measure>
    <time_frame>Day 1</time_frame>
    <description>The Anesthesiologist caring for the patient during the upper endoscopy made note of any obstructive events defined on a scale ranging from the patient audibly snoring (obstructing) to the patient obstructing and requiring assistance such as a chin lift or jaw thrust to relieve the obstruction and continue to move air adequately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Propofol Used During the Procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>Propofol doses are logged in the computerized Compurecord system used in the operating room. Patients involved in the study had their total Propofol dose required quantified and compared between groups who received Ketamine and groups who did not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sedation Required to Allow Initiation of Procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>Using the computerized record system, the amount of Propofol a patient required to allow for the procedure to start quantified and compared between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-operative Nausea and/or Vomiting</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergence Delirium</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants with emergence delirium measured from the procedure end until time of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery</measure>
    <time_frame>Day 1</time_frame>
    <description>Monitored via the electronic medical record system as the time between the anesthesia end time and when the patient was safe for discharge from the hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Obesity</condition>
  <condition>Bariatrics</condition>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Gastric Bypass</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>Ketofol and Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketofol</intervention_name>
    <description>50mg of Ketamine mixed with 100mg of Propofol</description>
    <arm_group_label>Ketofol and Propofol</arm_group_label>
    <other_name>Ketamine and Propofol</other_name>
    <other_name>Ketalar</other_name>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>100mg of Propofol</description>
    <arm_group_label>Ketofol and Propofol</arm_group_label>
    <arm_group_label>Propofol only</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>1mL of saline</description>
    <arm_group_label>Propofol only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 30

          -  Undergoing an upper gastrointestinal endoscopy

        Exclusion Criteria:

          -  History of schizophrenia/schizoaffective disorder

          -  History of bipolar disorder

          -  History of dementia

          -  Non-English Speaking

          -  History of Glaucoma

          -  Craniofacial Abnormalities

          -  Epilepsy

          -  Allergy to Propofol

          -  Allergy to Ketamine

          -  Current known intracranial mass/lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Maerz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tandon M, Pandey VK, Dubey GK, Pandey CK, Wadhwa N. Addition of sub-anaesthetic dose of ketamine reduces gag reflex during propofol based sedation for upper gastrointestinal endoscopy: A prospective randomised double-blind study. Indian J Anaesth. 2014 Jul;58(4):436-41. doi: 10.4103/0019-5049.138981.</citation>
    <PMID>25197112</PMID>
  </reference>
  <reference>
    <citation>Dal T, Sazak H, Tunç M, Sahin S, Yılmaz A. A comparison of ketamine-midazolam and ketamine-propofol combinations used for sedation in the endobronchial ultrasound-guided transbronchial needle aspiration: a prospective, single-blind, randomized study. J Thorac Dis. 2014 Jun;6(6):742-51. doi: 10.3978/j.issn.2072-1439.2014.04.10.</citation>
    <PMID>24976998</PMID>
  </reference>
  <reference>
    <citation>Street MH, Gerard JM. A fixed-dose ketamine protocol for adolescent sedations in a pediatric emergency department. J Pediatr. 2014 Sep;165(3):453-8. doi: 10.1016/j.jpeds.2014.03.021. Epub 2014 Apr 20.</citation>
    <PMID>24755240</PMID>
  </reference>
  <reference>
    <citation>Newton A, Fitton L. Intravenous ketamine for adult procedural sedation in the emergency department: a prospective cohort study. Emerg Med J. 2008 Aug;25(8):498-501. doi: 10.1136/emj.2007.053421.</citation>
    <PMID>18660398</PMID>
  </reference>
  <reference>
    <citation>Sih K, Campbell SG, Tallon JM, Magee K, Zed PJ. Ketamine in adult emergency medicine: controversies and recent advances. Ann Pharmacother. 2011 Dec;45(12):1525-34. doi: 10.1345/aph.1Q370. Epub 2011 Dec 6. Review.</citation>
    <PMID>22147144</PMID>
  </reference>
  <reference>
    <citation>Pambianco DJ. Future directions in endoscopic sedation. Gastrointest Endosc Clin N Am. 2008 Oct;18(4):789-99, x. doi: 10.1016/j.giec.2008.06.004. Review.</citation>
    <PMID>18922416</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <results_first_submitted>January 17, 2020</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2020</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Daniel Katz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Propofol</keyword>
  <keyword>Ketofol</keyword>
  <keyword>Obese</keyword>
  <keyword>Upper gastrointestinal endoscopy</keyword>
  <keyword>Sedation</keyword>
  <keyword>Bariatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02643979/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02643979/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketofol: Ketamine and Propofol</title>
          <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
        </group>
        <group group_id="P2">
          <title>Propofol Only</title>
          <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketofol: Ketamine and Propofol</title>
          <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
        </group>
        <group group_id="B2">
          <title>Propofol Only</title>
          <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.09" spread="16.0"/>
                    <measurement group_id="B2" value="44.63" spread="9.39"/>
                    <measurement group_id="B3" value="48.86" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="5.4"/>
                    <measurement group_id="B2" value="44" spread="8.3"/>
                    <measurement group_id="B3" value="42.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Class</title>
          <description>American Society of Anesthesiologists Classification (ASA Class)
ASA 1 A normal healthy patient
ASA 2 A patient with mild systemic disease
ASA 3 A patient with severe systemic disease
ASA 4 A patient with severe systemic disease that is a constant threat to life
ASA 5 A moribund patient who is not expected to survive without the operation
ASA 6 A declared brain-dead patient whose organs are being removed for donor purposes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="0.2"/>
                    <measurement group_id="B2" value="3" spread="0"/>
                    <measurement group_id="B3" value="2.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gagging Reaction</title>
        <description>Number of participants with gagging or &quot;vomit-like&quot; reaction on endoscopic insertion</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gagging Reaction</title>
          <description>Number of participants with gagging or &quot;vomit-like&quot; reaction on endoscopic insertion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Type of Airway Obstruction</title>
        <description>The Anesthesiologist caring for the patient during the upper endoscopy made note of any obstructive events defined on a scale ranging from the patient audibly snoring (obstructing) to the patient obstructing and requiring assistance such as a chin lift or jaw thrust to relieve the obstruction and continue to move air adequately.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Type of Airway Obstruction</title>
          <description>The Anesthesiologist caring for the patient during the upper endoscopy made note of any obstructive events defined on a scale ranging from the patient audibly snoring (obstructing) to the patient obstructing and requiring assistance such as a chin lift or jaw thrust to relieve the obstruction and continue to move air adequately.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Propofol Used During the Procedure</title>
        <description>Propofol doses are logged in the computerized Compurecord system used in the operating room. Patients involved in the study had their total Propofol dose required quantified and compared between groups who received Ketamine and groups who did not.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Propofol Used During the Procedure</title>
          <description>Propofol doses are logged in the computerized Compurecord system used in the operating room. Patients involved in the study had their total Propofol dose required quantified and compared between groups who received Ketamine and groups who did not.</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="19"/>
                    <measurement group_id="O2" value="39" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sedation Required to Allow Initiation of Procedure</title>
        <description>Using the computerized record system, the amount of Propofol a patient required to allow for the procedure to start quantified and compared between groups.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sedation Required to Allow Initiation of Procedure</title>
          <description>Using the computerized record system, the amount of Propofol a patient required to allow for the procedure to start quantified and compared between groups.</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="50.6"/>
                    <measurement group_id="O2" value="61" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-operative Nausea and/or Vomiting</title>
        <time_frame>up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-operative Nausea and/or Vomiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergence Delirium</title>
        <description>Number of participants with emergence delirium measured from the procedure end until time of discharge.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergence Delirium</title>
          <description>Number of participants with emergence delirium measured from the procedure end until time of discharge.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recovery</title>
        <description>Monitored via the electronic medical record system as the time between the anesthesia end time and when the patient was safe for discharge from the hospital.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketofol: Ketamine and Propofol</title>
            <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Propofol Only</title>
            <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recovery</title>
          <description>Monitored via the electronic medical record system as the time between the anesthesia end time and when the patient was safe for discharge from the hospital.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="9"/>
                    <measurement group_id="O2" value="25" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketofol and Propofol</title>
          <description>This arm received a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.</description>
        </group>
        <group group_id="E2">
          <title>Propofol Only</title>
          <description>This arm received 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Katz</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7475</phone>
      <email>daniel.katz@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

